Sold as Miochol, Miochol-E. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Acetylcholine Chloride (sold as Miochol, Miochol-E), first approved Oct 9, 1973, with 0 new uses approved and 0 published complete response letters.
| Acute Nicotine Gum and Auditory Brain Responses in Adults With Chronic TinnitusTinnitus, Chronic Subjective Tinnitus · San Diego State University | Phase 1 / Phase 2 | Not yet recruiting | Oct 16, 2026 |
| Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)Smoking Cessation · Axsome Therapeutics, Inc. | Phase 3 | Recruiting | Aug 14, 2026 |
| PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia GravisMyasthenia Gravis Generalized · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | — | Recruiting | Jul 21, 2026 |
| Trifecta Research StudyPTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction · Axial Therapeutic Research | — | Active, not recruiting | Jul 21, 2026 |
| Effect of Rg1-based Supplementation on Exercise Training-induced Stem Cell Recruitments and Skeletal Muscle Adaptation in Women Aged > 60Myeloid Cell Infiltration · University of Taipei | Not applicable | Not yet recruiting | Jul 14, 2026 |
| A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult ParticipantsHealthy Volunteers · Bristol-Myers Squibb | Phase 1 | Recruiting | Jun 18, 2026 |
| A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)Alzheimer Disease · Alpha Cognition, Inc | Phase 4 | Recruiting | Jun 8, 2026 |
| Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in WomenANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD) · Hospital de Clínicas Dr. Manuel Quintela | Not applicable | Recruiting | May 18, 2026 |
| Oct 9, 1973 | MiocholNDA 16211 · New molecular entity | Novartis | 15 | Discontinued |
| Sep 22, 1993 | Miochol-ENDA 20213 · New dosage form | Bausch And Lomb | 7 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis